A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States

Background. Chimeric antigen receptor (CAR) T-cell therapies are approved as second-line (2L) or later therapy for diffuse large B-cell lymphoma (DLBCL). Recently, bispecific T-cell antibodies (BsAbs) have been approved as third-line (3L) treatments. The cost-effectiveness of different treatment seq...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Anik R. Patel, Bradley Kievit, Ken Hasegawa, Markqayne Ray, Rishika Sharma, Sarahmaria Hofmann, Rob Blissett, Frederick L. Locke
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	SAGE Publishing 2025-06-01
Edice:	MDM Policy & Practice
On-line přístup:	https://doi.org/10.1177/23814683251345780
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!